Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC-R: Repurposed Drugs in Pre-ICU COVID-19 Patients
NCT04390464Phase 4Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ravulizumab, baricitinib in coronavirus disease 2019 (COVID-19), sponsored by Cambridge University Hospitals NHS Foundation Trust. Status: unknown.
02
Drugs
ravulizumabbaricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04390464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390464.